Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Completed
- Conditions
- Renal Transplantation
- Registration Number
- NCT00842699
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- all patients considered for transplantation
Exclusion Criteria
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is to look for expansion of regulatory T cells at one year. 12 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Thymoglobulin modulates T-cell populations in renal transplant recipients?
How does Basiliximab compare to Thymoglobulin in suppressing IL-2 receptor activity for renal transplant immunosuppression?
Which biomarkers correlate with graft acceptance in patients treated with Thymoglobulin versus Basiliximab post-transplant?
What are the long-term adverse event profiles of Thymoglobulin and Basiliximab in renal transplant immunosuppressive regimens?
How do Thymoglobulin and Basiliximab combination therapies compare to standard-of-care induction treatments in renal transplantation?
Trial Locations
- Locations (1)
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital🇺🇸Boston, Massachusetts, United States